A middle aged man looking pensive
About us

AT A GLANCE

With a unique heritage in dermatology as well as decades of cutting-edge innovation, Galderma is the leading company solely dedicated to advancing dermatology for every skin story. We are strategically positioned in attractive, consumer-driven segments of the dermatology market, characterized by high growth fundamentals. Through trusted partnerships with healthcare professionals, we ensure to meet individual consumer and patient needs with superior outcomes.

KEY FACTS ABOUT GALDERMA

3.760 B USD

2022 net sales

4

manufacturing sites

Global presence

we operate from 50 sites in 40 countries, with our headquarters in Switzerland

 

620+

clinical trials funded across 30+ countries since 2020

131

major health authority approvals since 2020

 

100,000+

aesthetics healthcare professionals trained via our Global Aesthetic Injector Network (GAIN) program in 2022

Flemming Ornskov-GALDERMA-9679(940x400).jpg

LEADERSHIP

Find out about our leadership team by clicking here.

A timeline of our history

1981
Foundation of Galderma as a joint venture between L’Oréal and Nestlé

Following the invention of the first Cetaphil formulation in 1947

1984
Galderma discovers Adapalene

1986
First commercial operations

1995
Launch of Differin for acne treatment

2000
Opening of our production site in Baie d’Urfé, Canada

2001
Licensing agreement for Metvix (Skin cancer)

2004
Opening of our production site in Hortolândia, Brazil

2007
Launch of Differin 0.3%

2008
Launch of Epiduo

2009
Launch of Azzalure and Restylane Injector

 

 

2009
Acquisition of Sculptra

2011
Acquisition of Q-med, maker of Restylane

2014
Nestlé Skin Health is founded – Galderma becomes a wholly-owned subsidiary of Nestlé

2019
Galderma debuts as the world’s largest independent global dermatology company following acquisition by a consortium of institutional investors

2021
Acquisition of Alastin Skincare

2022
Divestment of Alchemee

2022
Launch of Alluzience